High-mobility group box 1 and the receptor for advanced glycation end products contribute to lung injury during  pneumonia by unknown
Achouiti et al. Critical Care 2013, 17:R296
http://ccforum.com/content/17/6/R296RESEARCH Open AccessHigh-mobility group box 1 and the receptor for
advanced glycation end products contribute to
lung injury during Staphylococcus aureus
pneumonia
Ahmed Achouiti1,2*, Anne Jan van der Meer1,2, Sandrine Florquin3, Huan Yang4, Kevin J Tracey4,
Cornelis van ’t Veer1,2, Alex F de Vos1,2 and Tom van der Poll1,2,5Abstract
Introduction: Staphylococcus (S.) aureus has emerged as an important cause of necrotizing pneumonia. Lung injury
during S. aureus pneumonia may be enhanced by local release of damage associated molecular patterns such as
high-mobility group box 1 (HMGB1). In the current study we sought to determine the functional role of HMGB1
and its receptors, toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE), in the
injurious host response to S. aureus pneumonia.
Methods: Pneumonia was induced in wild type (Wt), TLR4 deficient (tlr4−/−) and RAGE deficient (rage−/−) mice by
intranasal inoculation of 1 × 107 colony-forming units (CFU) of a USA300 S. aureus. In a separate set of experiments,
Wt mice were injected intraperitoneally with a monoclonal anti-HMGB1 antibody or an isotype matched control
antibody immediately before and every 24 hours after intranasal infection of S. aureus. Mice were sacrificed at 6, 24,
48 or 72 hours after infection for harvesting of blood and organs.
Results: S. aureus pneumonia was associated with HMGB1 release in the bronchoalveolar compartment peaking
after 24 hours. Anti-HMGB1 attenuated lung pathology and protein leak and reduced interleukin-1β release 6 hours
after infection, but not at later time points. RAGE deficiency more modestly attenuated lung pathology without
influencing protein leak, while TLR4 deficiency did not impact on lung injury.
Conclusion: These data suggest that HMGB1 and RAGE, but not TLR4, contribute to lung injury accompanying the
early phase of S. aureus pneumonia.Introduction
The Gram-positive bacterium Staphylococcus (S.) aureus
is a frequent colonizer of the human body, and when the
opportunity arises, is able to cause a wide array of clin-
ical syndromes [1]. Infections caused by this pathogen
impose a high burden on healthcare, largely due to the
increasing incidence of antibiotic resistance [2]. Over
the past few years, highly virulent methicillin-resistant* Correspondence: a.achouiti@amc.uva.nl
1Center for Experimental and Molecular Medicine, Meibergdreef 9, Room
G2-130, Amsterdam 1105 AZ, The Netherlands
2Center for Infection and Immunity, Academic Medical Center, University of
Amsterdam, Meibergdreef 9, Room G2-130, Amsterdam 1105 AZ, The Netherlands
Full list of author information is available at the end of the article
© 2013 Achouiti et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orS. aureus strains, in particular USA300, have become
prevalent in the community as well [2] and have emerged
as an important cause of (necrotizing) pneumonia [3].
Pneumonia caused by these strains have a fulminant onset
determined by staphylococcal virulence factors and the na-
ture of the immune response [3,4]. More insight into
pathogenic mechanisms that influence the outcome of
lower airway infection by S. aureus could help in the devel-
opment of new (immunomodulating) therapies.
Staphylococcal pneumonia is associated with a massive
influx of neutrophils and release of cytotoxic granular
proteins [5-7]. Together with invasive infection, intense
host defense mechanisms likely contribute to lung tissue
damage and release of damage-associated molecularl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that engage with these self-derived proteins may contribute
to the severity of pneumonia as they perpetuate (excessive)
inflammation. High-mobility group box 1 (HMGB1) is a
DAMP that may be of particular interest as it is associated
with delayed and sustained release during infection [9].
HMGB1 is a highly conserved non-histone nuclear protein,
which is either released passively during cell injury or se-
creted actively upon inflammatory stimuli [9]. Depending
on specific posttranslational redox modifications HMGB1
can act as a cytokine via receptors such as the receptor for
advanced glycation end products (RAGE) and toll-like
receptor (TLR)4 or as a chemotactic factor by forming
a heterocomplex with the chemokine CXCL12 via the che-
mokine receptor CXCR4 [10].
In this study we investigated the role of HMGB1 in ex-
perimentally induced S. aureus pneumonia. This newly
developed mouse model of pneumonia is associated with
severe pulmonary inflammation and massive influx of
neutrophils. In order to study the role of HMGB1 in the
pathogenesis of S. aureus lung infection we inoculated
wild-type (Wt) mice with a USA300 strain of S. aureus
and treated animals with a control or an anti-HMGB1
antibody. In addition, we investigated Wt mice and mice
deficient for TLR4 or RAGE, the receptors implicated in
mediating the proinflammatory effects of HMGB1, after
induction of S. aureus pneumonia.
Methods
Ethics statement
Experiments were carried out in accordance with the
Dutch Experiment on Animals Act and approved by the
Animal Care and Use Committee of the University of
Amsterdam (Permit number: DIX100121).
Mice
C57Bl/6 Wt mice were purchased from Charles River
Laboratories Inc. (Maastricht, the Netherlands). RAGE-
deficient (rage−/−) [11] and tlr4−/− mice [12], back-
crossed >10 times to a C57BL/6 background were
generated as described and bred in the animal facil-
ity of the Academic Medical Center (Amsterdam, the
Netherlands).
Design
Wt, Rage−/− and tlr4−/− mice were lightly anesthe-
sized by inhalation of isoflurane (Abbot Laboratories,
Queensborough, Kent, UK) and intranasally inoculated
with a sub-lethal dose of 1 × 107 S. aureus USA300 (BK
11540) in a 5-μl saline solution (n = 7 to 8 per strain).
This sub-lethal dose was determined in a pilot study: mice
that were intranasally inoculated with 1 × 108 S. aureus
died after 24 hours, whereas mice that were infected with
1 × 107 S. aureus were clinically ill, but remained alive until72 hours after infection (data not shown). In separate
experiments Wt mice were injected intraperitoneally with
either 150 μg monoclonal anti-HMGB1 (2G7, IgG2b;
Cornerstone Therapeutics, Cary, NC, USA) or an isotype-
matched control antibody (MOPC-195, IgG2b; Sigma, St.
Louis, MO, USA) in 100 μl PBS) immediately before and
every 24 hours after intranasal infection of S. aureus. The
dose of this anti-HMGB1 monoclonal antibody was se-
lected according to a previous study and is able to effect-
ively inhibit HMGB1 induced pathology in a mouse model
of infectious lung injury [13]. Mice were sacrificed at 6, 24,
48 or 72 hours after infection.
Bacterial cultures
Measurements of bacterial loads were done as described
previously [14]. In brief, blood was drawn into heparin-
ized tubes, bronchoalveolar lavage (BAL) fluid was ob-
tained as described below and organs were removed
aseptically and homogenised in four volumes of sterile
isotonic saline using a tissue homogenizer (Biospec
Products, Bartlesville, OK, USA). To determine bacterial
loads, ten-fold dilutions were plated on blood agar plates
and incubated at 37°C for 16 hours.
Bronchoalveolar lavage
The trachea and bronchi were exposed through a midline
incision. The left main bronchus was ligated and the tra-
chea was cannulated with a sterile 22-gauge Abbocath-T
catheter (Abbott Laboratories, Sligo, Ireland). Unilateral,
right-sided BAL was performed by instilling three 0.3-ml
aliquots of sterile PBS: 0.7 to 0.9 ml of BAL fluid was
retrieved per mouse. Total cell numbers in BAL were
counted using a Z2 Coulter particle count and size
analyzer (Beckman-Coulter, Inc., Miami, FL, USA). BAL
fluid differential cell-counts were determined on cytospin
preparations stained with a modified Giemsa stain (Diff-
Quick; Baxter, McGraw Park, IL, USA).
Assays
Cytokines and chemokines TNF-α, IL-1β, IL-6, IL-10,
keratinocyte-derived chemokine (KC) and macro-
phage inflammatory protein (MIP)-2 (all R&D systems,
Minneapolis, MN, USA) were measured in BAL fluid
using specific ELISAs according to manufacturer’s rec-
ommendations. Total protein concentrations were mea-
sured using a DC protein assay (Bio-Rad Laboratories,
Veenendaal, The Netherlands).
HMGB1 western blot
For western blotting of HMGB1, non-reduced BAL fluid
samples from Wt mice were diluted with 3× Laemmli
buffer (n = 5 per time point). After heating, samples
were run on 15% polyacrylamide SDS gels and subse-
quently transferred to blotting membrane (polyvinylidene
Figure 1 High mobility group box 1 (HMGB1) concentrations in
mouse bronchoalveolar lavage (BAL) fluid during S. aureus
pneumonia. Wt mice were intranasally infected with 1 × 107 colony
forming units (CFU) S. aureus and euthanized after 6, 24, 48 and
72 hours. HMGB1 concentrations in BAL fluid were quantified by
densometric analysis of HMGB1 western blots and expressed as a
percentage of the mean density of control BAL fluid samples (0 hours).
Data represent the means ± standard error of the mean (n = 5 mice per
time point). *P <0.05 versus naïve mice (0 hours).
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NJ, USA). Following blocking with 5% nonfat dry milk pro-
teins (Protifar; Nutricia, Zoetermeer, The Netherlands)
in 0.1% Tween 20 PBS (PBS-T), membranes were washed
and incubated overnight in 1 μg/ml primary rabbit anti-
HMGB1 polyclonal antibody (Abcam, Cambridge, UK)
in 1% nonfat dry milk proteins in PBS-T at 4°C. After
washing with PBS-T, membranes were probed with anti-
rabbit-HRP-conjugated secondary antibody (Cell Signaling
Technology, Danvers, MA, USA) for 1 hour at room
temperature in 1% bovine serum albumin in PBS-T.
After washing with PBS-T, membranes were incubated
with Lumi-Light Plus Western Blotting Substrate (Roche,
Mijdrecht, The Netherlands) and positive bands were de-
tected using an LAS3000 Luminescent image Analyzer
dark box (Fujifilm, Tokyo, Japan). Band densities were
determined using AIDA Image analyzer software (Raytest,
Straubenhardt, Germany) and expressed as a percentage of
band densities of naive control samples.
Histology
Lung pathology scores were determined as described be-
fore [14]. In brief, the left lung lobe was harvested at the
indicated time points, fixed in 10% buffered formalin,
and embedded in paraffin: 4-μm sections were then
stained with H&E and analyzed by a pathologist blinded
for groups. To score lung inflammation and damage, the
entire lung surface was analyzed with respect to the follow-
ing parameters: bronchitis, edema, interstitial inflamma-
tion, intra-alveolar inflammation, pleuritis, endothelialitis
and percentage of the lung surface demonstrating conflu-
ent inflammatory infiltrate. Each parameter was graded 0
to 4, with 0 representing absent and 4 representing severe.
The total pathology score was expressed as the sum of the
score for all parameters.
Statistical analysis
Data are expressed as box-and-whisker diagrams depict-
ing the smallest observation, lower quartile, median,
upper quartile and largest observation unless indicated
otherwise. Differences between groups of mice were ana-
lyzed by the Mann-Whitney U-test. Analyses were done
using GraphPad Prism version 5.0, Graphpad Software
(San Diego, CA, USA). Values of P <0.05 were considered
significantly different.
Results
HMGB1 is released in bronchoalveolar lavage fluid during
staphylococcal pneumonia
To examine HMGB1 release in murine S. aureus pneumo-
nia we performed a western blot by running non-reduced
BAL fluid samples harvested at various time points in Wt
mice after intranasal inoculation of a sublethal dose of
S. aureus. Uninfected mice displayed almost no detectablelevels of HMGB1. HMGB1 bands were detected as early as
6 hours post infection. HMGB1 concentrations peaked
after 24 hours and decreased thereafter (Figure 1).HMGB1 and RAGE, but not TLR4, contribute to lung
pathology
To evaluate the role of HMGB1, RAGE and TLR4 in the
severity of lung pathology, we analyzed pulmonary in-
flammation and injury in lung-tissue slides obtained
from anti-HMGB1 treated, rage−/− and tlr4−/− mice and
their respective control animals at 6, 24, 48 and 72 hours
after infection with S. aureus (Figures 2 and 3). Total
pathology scores were quantified according to the scor-
ing system described in the Methods section. Mice
already displayed signs of acute lung injury including
interstitial inflammation, endothelialitis, bronchitis and
pleuritis after 6 hours; the extent of lung pathology upon
histological examination remained relatively stable there-
after. At 6 hours post infection, anti-HMGB1 treatment
reduced total pathology scores (P <0.01 versus Wt mice),
which was mostly caused by a reduction of lung edema
compared to control antibody treatment (Figure 2A-E).
In accordance, anti-HMGB1 attenuated protein leak
into the bronchoalveolar space at this early time point,
as reflected by lower total protein concentrations in
BAL fluid (P <0.01 versus Wt mice). At later time points
anti-HMGB1 did not impact on the extent of lung path-
ology or protein leak.
Figure 2 Anti-high mobility group box 1 (HMGB1)-treated mice show reduced lung pathology early after induction of S. aureus pneumonia.
Representative slides of lung H&E staining of control treated (A) and anti-HMGB1 treated mice (C), original magnification × 2. The boxed areas are also
shown at a higher magnification for controls (B) and anti-HMGB1-treated mice (D), original magnification× 10. Scale bars indicate 200 μm. Total
pathology scores were determined at the indicated time points post infection in control treated (gray) and anti-HMGB1 treated mice (white)
according to the scoring system described in the Methods section (E). Total protein was measured in BAL fluid from control (grey) and anti-HMGB1
treated (white) mice (F). Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile
and largest observation (7 to 8 mice per group at each time point). **P <0.01 versus control treated mice at the same time point.
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(Figure 3). Rage−/− mice, however, displayed modestly at-
tenuated lung pathology at 6 hours post infection (P <0.05
versus Wt mice), which was primarily caused by reduced
pleuritis. Although total lung pathology scores were similar
in rage−/− and Wt mice at later time points, the former
mouse strain did show significantly smaller areas of con-
fluent inflammatory infiltrates at 48 hours after infection
(17 ± 5% of their lung surface versus 31 ± 2% in Wt mice,
mean ± standard error of the mean, P <0.05, Additional
file 1: Figure S1). Remarkably, while RAGE deficiency did
not impact on total protein levels in BAL fluid, tlr4−/−mice displayed an increase of BAL fluid total protein
content 6 hours after infection (P <0.01 versus Wt mice).
In conclusion, these data indicate that RAGE and
HMGB1 contribute to the extent of lung pathology in
S. aureus pneumonia, but, considering their differential
impact on histological features, most likely via different
mechanisms.
HMGB1 or RAGE do not influence neutrophil influx during
staphylococcal pneumonia
One of the hallmarks in S. aureus pneumonia is a
massive influx of neutrophils into the lung parenchyma
Figure 3 Receptor for advanced glycation end products (Rage) −/− but not Toll-like receptor (tlr)4−/− mice show reduced lung pathology
during S. aureus pneumonia. Representative slides of lung HE staining of wild-type (Wt) (A), tlr4−/− (C) and rage−/− mice (E), original
magnification × 2. The boxed areas are also shown at a higher magnification for Wt (B) tlr4−/− (D) and rage−/− mice (F), original magnification × 10.
Scale bars indicate 200 μm. Total pathology scores at indicated time points after intranasal infection with S. aureus in Wt (dark gray), tlr4−/− (light gray)
and rage−/− mice (white) were determined according to the scoring system described in the Methods section (G). Total protein was measured
in bronchoalveolar lavage (BAL) fluid from Wt (dark gray), tlr4−/− (light gray) and rage−/− mice (white) at the indicated time points after intranasal
S. aureus infection (H). Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and
largest observation (7 to 8 mice per group at each time point). *P <0.05, **P <0.01 versus Wt mice at the same time point.
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BAL fluid at any time after infection with S. aureus
(Table 1). Similarly, RAGE or TLR4 deficiency did not im-
pact on neutrophil influx, except for modestly lower neu-
trophil numbers in BAL fluid of tlr4−/− mice harvested 72
hours after infection (Table 2, P <0.05 versus Wt mice).Table 1 Influx of neutrophils in bronchiolar lavage fluid
of control or anti-HMGB1-treated mice
Time point (t) Control IgG2b Anti-HMGB1
t = 6 h 508 (390 to 1169) 520 (207 to 736)
t = 24 h 434 (391 to 580) 665 (450 to 934)
t = 48 h 1376(1054 to 1796) 1339 (1147 to 1770)
t = 72 h 600 (516 to 891) 519(425 to 841)
Neutrophil numbers (×1,000/ml) in BAL fluid at 6, 24, 48 and 72 hours after
intranasal S. aureus infection in control and anti-HMGB1-treated mice. Data are
medians (interquartile ranges); n = 7 to 8 mice per group per time point.
HMGB1, High mobility group box 1.RAGE and HMGB1, but not TLR4, contribute to pulmonary
cytokine and chemokine release early after infection with
S. aureus
To further investigate the role of HMGB1 in lung in-
flammation during S. aureus pneumonia we measured
cytokines (TNF-α, IL-1β and IL-6) and chemokines (KCTable 2 Influx of neutrophils in bronchiolar lavage fluid
of wild-type, tlr4−/− or Rage−/− mice
Time point (t) Wild-type Tlr4−/− Rage−/−
t = 6 h 239 (217 to 310) 397 (221 to 535) 526 (350 to 647)
t = 24 h 298 (250 to 380) 236 (196 to 275) 342 (262 to 404)
t = 48 h 429 (218 to 652) 522 (421 to 756) 395 (314 to 541)
t = 72 h 146 (99 to 190) 90 (81 to 132) 76 (47 to 104)*
Neutrophil numbers (×1000/ml) in bronchiolar lavage fluid at 6, 24, 48 and 72
hours after intranasal S. aureus infection in wild-type (Wt), Toll-like receptor (tlr)
4−/− and Receptor for advanced glycation end products (Rage)−/− mice. Data are
medians (interquartile ranges); n = 7 to 8 mice per group per time point. *P <0.05
versus Wt mice at the same time point.
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HMGB1 or control antibody (Figure 4). All cytokines
and chemokines reached peak concentrations at 6 hours
after infection. At this time point anti-HMGB1 treatment
decreased IL-1β concentrations in BAL fluid (P <0.05
versus mice treated with control antibody), without influ-
encing the levels of other proinflammatory mediators. At
later time points, cytokine and chemokine levels were
low in all mice and not different between groups with the
exception of lower KC levels in anti-HMGB1 treated
mice at 48 hours. Cytokine levels in BAL fluid of tlr4−/−
mice were similar to those in Wt mice at all time points;
tlr4−/− mice showed lower KC concentrations at 48 hours
relative to Wt mice (Figure 5). Rage−/− mice had lower
TNF-α and IL-6 levels at 24 hours of infection and lower
KC concentrations at 24 and 48 hours when compared
with Wt mice.
HMGB1 does not influence bacterial clearance during
staphylococcal pneumonia
HMGB1 has been shown to impair bacterial clearance dur-
ing pneumonia caused by Pseudomonas (P.) aeruginosa
[13,15]. To investigate the role of HMGB1 in clearance of
S. aureus, we quantified bacterial loads in BAL fluid, liver
and blood after intranasal inoculation with 107 S. aureus
of mice treated with anti-HMGB1 or control antibody.Figure 4 Anti-high mobility group box 1 (HMGB1) treatment reduces IL-
lavage (BAL) fluid after intranasal infection with S. aureus. Cytokine (TNF-α
protein (MIP)-2) (D-E) levels in BAL fluid at different time points after intranasal
with control (gray) and anti-HMGB1 antibodies (white). Data are expressed as b
lower quartile, median, upper quartile and largest observation (7 to 8 mice per
time point.Although HMGB1 was highly present at the primary site
of infection during S. aureus pneumonia, anti-HMGB1
treatment did not influence bacterial loads at any time
point (Figure 6A).
We next investigated the role of TLR4 and RAGE in
bacterial clearance. In analogy to the results obtained
after anti-HMGB1 treatment, tlr4−/− mice showed similar
bacterial loads as Wt mice at all time points (Figure 6B).
Rage−/− mice displayed 10 times lower bacteria in BAL
fluid after 6 hours (P <0.01 versus Wt mice), but not at
later time points (Figure 6B). Bacteria that disseminated
into the circulation were almost immediately cleared in all
mice. No differences in bacterial loads in blood or livers
were observed between experimental groups (data not
shown). Together these data indicate that RAGE impairs
clearance of S. aureus in the bronchoalveolar compart-
ment early after infection and that HMGB1 has no role
herein. Moreover, TLR4 does not contribute antibacterial
defense during S. aureus pneumonia.
Discussion
S. aureus is a major bacterial pathogen responsible for
both healthcare and community-associated infections
[1]. Pulmonary infection by S. aureus may develop into
necrotizing pneumonia and can be very severe as a conse-
quence of both virulence factors and an intense immune1β and keratinocyte-derived chemokine (KC) levels in bronchiolar
, IL-6 and IL-1β) (A-C) and chemokine (KC and macrophage inflammatory
infection of 1 × 107 colony-forming units (CFU) S. aureus in mice treated
ox-and-whisker diagrams depicting the median, the smallest observation,
group at each time point). *P <0.05, **P <0.01 versus Wt mice at the same
Figure 5 Receptor for advanced glycation end products (Rage)−/− mice show lower levels of TNF-α and IL-6 in bronchiolar lavage (BAL)
fluid during S. aureus pneumonia. Cytokine (TNF-α, IL-6 and IL-1β) (A-C) and chemokine (keratinocyte-derived chemokine (KC) and macrophage
inflammatory protein (MIP)-2) (D-E) levels 6, 24, 48 and 72 hours after intranasal S. aureus infection in Wt (dark gray) and tlr4−/− (light gray) and rage−/−
mice (white). Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest
observation (7 to 8 mice per group at each time point). *P <0.05, **P <0.01 versus Wt mice.
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enhancement of inflammation caused by the release of
DAMPs such as HMGB1 [4,7,8]. In the current study we
intranasally challenged mice with staphylococci to deter-
mine the functional role of HMGB1 and two of its proin-
flammatory receptors in S. aureus pneumonia [9]. We
showed that S. aureus pneumonia is associated with
HMGB1 release in the bronchoalveolar compartment
peaking after 24 hours. Although relatively little HMGB1Figure 6 Bacterial outgrowth in Receptor for advanced glycation end p
with S. aureus. Bacterial loads after intranasal infection with 1 × 107 colony
mice treated with control (gray) and anti-HMGB1 antibodies (white) and in
and rage−/− mice (white) at 6, 24, 48 and 72 hours after infection. Data are
smallest observation, lower quartile, median, upper quartile and largest ob
versus Wt mice at the same time point.was released at 6 hours, anti-HMGB1 treatment was able
to attenuate lung pathology and protein leak, accompanied
by lower IL-1β concentrations in BAL fluid at this time
point. TLR4, which has been identified as the dominant
proinflammatory receptor for HMGB1 [10], had no im-
pact, or very limited impact on the injurious host response
during S. aureus pneumonia. RAGE deficiency, how-
ever, was associated with reduced lung pathology although
rage−/− mice did not phenocopy anti-HMGB1 treated mice,roducts (Rage)−/− mice is reduced early after intranasal infection
-forming units (CFU) S. aureus in bronchiolar lavage (BAL) fluid (A) of
BAL fluid (B) of Wt (dark gray), Toll-like receptor (tlr)4−/− (light gray)
expressed as box-and-whisker diagrams depicting the median, the
servation (n = 7 to 8 mice per group at each time point). **P <0.01
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sults suggest a harmful role for both HMGB1 and RAGE
in the development of lung injury during the early phase of
severe pneumonia caused by a clinical relevant Gram-
positive pathogen.
Previous studies investigated the role of HMGB1 in
lung injury associated with Gram-negative pneumonia in
mice with various comorbid conditions [13,15]. Anti-
HMGB1 treatment attenuated pulmonary neutrophil re-
cruitment and lung injury upon airway infection with
P. aeruginosa of mice deficient for the cystic fibrosis
transmembrane conductance regulator [13] and mice
exposed to hyperoxia [15]. In accordance, anti-HMGB1
decreased neutrophil accumulation and lung edema in
mice treated with intratracheal endotoxin [16], the pro-
inflammatory component of the Gram-negative bacterial
cell wall. Moreover, HMGB1 has been reported to con-
tribute to hemorrhage- and ventilator-induced lung in-
jury in mice [17,18]. To the best of our knowledge, our
investigation is the first to study the role of HMGB1 in
lung injury elicited by a Gram-positive pathogen. For
this we administered a monoclonal anti-HMGB1 anti-
body previously shown to inhibit HMGB1-induced acute
and chronic inflammation in mice [13,19], including
pneumonia [13]. Although HMGB1 levels only tended
to increase 6 hours after induction of S. aureus pneumo-
nia, anti-HMGB1 reduced protein leak and lung edema
at this time point, which is in accordance with results
obtained during Gram-negative pneumonia [13,15,16],
In contrast, we did not find a role for HMGB1 in neu-
trophil recruitment, which at least in part may be ex-
plained by differential pattern recognition receptors and
integrins involved in attraction of neutrophils to the
lungs by Gram-negative and Gram-positive stimuli [6].
The current model of S. aureus pneumonia is associ-
ated with a strong early and transient cytokine and che-
mokine response in the bronchoalveolar space, peaking
after 6 hours. Although HMGB1 was not statistically sig-
nificantly increased at 6 hours, antagonizing this rela-
tively low level of HMGB1 diminished the greatly
enhanced IL-1β levels in BAL fluid, which may have
contributed to reduced protein leak and pathology at
this time point. In accordance, anti-HMGB1 was previ-
ously shown to inhibit IL-1β release after airway endo-
toxin exposure and in pulmonary injury induced by
hemorrhage [16,17]. Interestingly enough, we could not
find differences in other cytokines at this time point.
These seemingly discrepant results are not easily explained
and require further investigation. As cytokine production
was considerably reduced at time points later than 6 hours
in all groups, blockade of HMGB1 from 24 hours onward
had only little effect. As such, the brisk induction of
inflammatory mediators after intrapulmonary delivery of
S. aureus is most likely initiated via a TLR2-MyD88dependent mechanism [20], while the subsequent release
of HMGB1 apparently does not sustain this response,
although anti-HMGB1 reduced the already low KC levels
in BAL fluid at 48 hours.
Several receptors have been implicated in mediating
cellular effects of HMGB1 [9]. Purified HMGB1 binds
specifically to TLR4 to induce proinflammatory cytokine
release by an interaction that requires a cysteine in pos-
ition 106 [10]. In addition, HMGB1 can mediate proin-
flammatory effects by binding of partner molecules such
as bacterial ligands, extracellular cell free DNA, nucleo-
somes and IL-1β, through which other pattern recogni-
tion receptors can be activated [9]. Our group previously
showed that intraperitoneal injection of recombinant
HMGB1 induces inflammation by mechanisms that par-
tially depend on TLR4 and RAGE [21]. We showed that
TLR4 is not involved in the lung pathology induced by
S. aureus. We did not expect a direct role for TLR4 in
the initiation of lung inflammation induced by S. aureus,
considering that this pathogen does not express known
TLR4 ligands [20]. Of note, however, TLR4 not only can
function as a receptor for HMGB1, but also for other
DAMPs released upon acute lung injury [22]. As such,
our results argue against an important role for TLR4 as
a DAMP receptor contributing to lung injury during
S. aureus pneumonia. In contrast, earlier investigations
reported a clear role for HMGB1-TLR4 signaling in
sterile-injury models induced by ischemia-reperfusion
[23] and trauma [24]. Remarkably, TLR4 seemed to pro-
tect against epithelial barrier disruption, as indicated by
increased protein levels in BAL fluid of tlr4−/− mice early
after infection. Previous studies reported reduced epithe-
lial barrier integrity in hyperoxia-induced lung injury in
tlr4−/− and C3H/HeJ mice by a mechanism that involved
a diminished capacity to upregulate anti-apoptotic pro-
teins [25,26]. Further studies are warranted to establish
the mechanism by which TLR4 protects against alveolar
protein leak during S. aureus pneumonia.
RAGE has been implicated in lung injury induced by
hyperoxia [27] or bleomycin [28]. In addition, in pneu-
monia caused by Streptococcus pneumoniae, rage−/− mice
have shown mitigated lung injury and neutrophil migration
[29]. Nonetheless, Rage−/− mice showed only discreetly
attenuated lung pathology at 6 hours after infection with
S. aureus without alterations in neutrophil recruitment or
protein leak. Rage−/− mice did demonstrate reduced TNFα,
IL-6 and KC concentrations in BAL fluid 24 hours post in-
fection. Thus, although RAGE contributed to lung inflam-
mation during experimental S. aureus pneumonia, its role
was modest and was unlikely to be mediated by HMGB1.
RAGE can interact with several other ligands including ad-
vanced glycation end-products, amyloid, β-sheet fibrils and
members of the S100 protein family [9]. Which RAGE lig-
and(s) contribute to its effects in S. aureus pneumonia
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mice displayed increased clearance of S. aureus from the
bronchoalveolar compartment is in line with an earlier
study from our laboratory reporting attenuated bacterial
growth and dissemination in rage−/− mice after induction
of pneumonia by Streptococcus pneumoniae [29].
Conclusions
In conclusion, we here describe distinct roles for
HMGB1 and RAGE in lung injury accompanying the
early phase of S. aureus pneumonia. HMGB1 is a proin-
flammtory mediator which is released in the bronchoal-
veolar compartment and contributes to protein leak and
lung edema, while it does not influence neutrophil re-
cruitment or bacterial clearance. Although TLR4 has
been implicated as the dominant proinflammatory recep-
tor for HMGB1 [10], this receptor had only limited im-
pact on the injurious host response during S. aureus
pneumonia. RAGE deficiency, however, was associated
with reduced lung pathology and inflammation as well,
suggesting that both HMGB1 and RAGE are harmful in
the development of lung injury during the early phase of
severe S. aureus pneumonia.
The current finding that neither anti-HMGB1 nor de-
ficiency for the major DAMP receptors RAGE or TLR4
impact on the sustained lung pathology accompanying
S. aureus pneumonia suggest that other DAMPs and
receptors are involved. Candidates meriting further
investigation include TLR3 (extracellular RNA), TLR9
(extracellular DNA) and the inflammasomes (multiple
DAMPs).
Key messages
 S. aureus pneumonia is associated with early (6 hours
after infection) bronchoalveolar HMGB1 release,
which contributes to inflammation, protein leak and
lung edema
 TLR4 has only limited impact on the injurious host
response during S. aureus pneumonia
 RAGE enhances pulmonary inflammation and
pathology early after intranasal S. aureus infection
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Additional file 1: Figure S1. Receptor for advanced glycation end
products (Rage) −/− show smaller areas of confluent inflammatory
infiltrates at 48 hours after S. aureus infection. Representative slides of
lung HE staining of wild-type (Wt) (A), Toll-like receptor (tlr)4−/− (B) and
rage−/− mice (C) at 48 hours after infection, original magnification × 2.
Scale bars indicate 200 μm. The percentage of the lung surface demonstrating
confluent inflammatory infiltrate was determined in Wt (dark gray), tlr4−/−
(light gray) and rage−/− mice (white) (D). Data are expressed as box-and-
whisker diagrams depicting the smallest observation, lower quartile, median,
upper quartile and largest observation (7 to 8 mice per group at each time
point). *P <0.05 versus Wt mice at the same time point.Abbreviations
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DAMPs: Damage-associated molecular patterns; ELISA: Enzyme-linked
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